Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFRMutated NSCLC in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis December 10, 2024
Long-Term Follow-up Study to the OLYMPUS Trial Reports Median Duration of Response of 4 Years in Patients Who Achieved a Complete Response with JELMYTO® December 10, 2024
Positive Results Announced from Ph 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC December 10, 2024
FAILED TRIAL: Ph 3 KEYLYNK-001 Trial Met Primary Endpoint of PFS, but not OS, in Patients With Advanced Epithelial Ovarian Cancer December 10, 2024
Positive Topline Results from Ph 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Announced December 4, 2024
FAILED TRIAL: Ph 3 SKYSCRAPER-01 study of tiragolumab + Tecentriq in patients with PD-L1-high 1L mNSCLC did not reach the primary endpoint of OS December 4, 2024
Positive Initial Clinical Data Announced in Ph 1 Clinical Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML December 4, 2024
New Data from the OLYMPUS Trial Show mDOR of Four Years in Patients Who Achieved a Complete Response with JELMYTO December 4, 2024
Positive Final Results from Randomized Ph 2 Study of CM24 in 2L Pancreatic Cancer Reported December 4, 2024
ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial Completed and CRR of 71% with a Durable DoR Ranging Up to 54 Months reported November 26, 2024
Ph 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints November 26, 2024
Truqap combination in PTEN-deficient mHSPC demonstrated statistically significant and clinically meaningful improvement in rPFS in CAPItello-281 Ph 3 trial November 26, 2024
Eflornithine and Lomustine Combination Shows Clinically Meaningful Improvements in OS and PFS in Patients with Recurrent Astrocytoma IDH Mutant Grade 3 November 26, 2024
FAILED TRIAL: Topline Data Announced from SELECT-MDS-1 Ph 3 Trial of Tamibarotene in Higher-Risk MDS with RARA Gene Overexpression November 19, 2024
ECLIPSE Trial Meets Primary Endpoint, Showing a Statistically Significant & Clinically Meaningful Benefit for Patients With PSMA+ve metastatic CRPC November 19, 2024
Annamycin + Ara-C achieved 60% CR/CRi in AML patients who were relapsed from or refractory to Venetoclax regimens November 19, 2024
